The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration

OBJECTIVE: The sodium-glucose transporter 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin are recently approved medications for type 2 diabetes. Recent studies indicate that SGLT2 inhibitors may inhibit the growth of some cancer cells but the mechanism(s) remain unclear. METHODS: Cellular proli...

Descripción completa

Detalles Bibliográficos
Autores principales: Villani, Linda A., Smith, Brennan K., Marcinko, Katarina, Ford, Rebecca J., Broadfield, Lindsay A., Green, Alex E., Houde, Vanessa P., Muti, Paola, Tsakiridis, Theodoros, Steinberg, Gregory R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034684/
https://www.ncbi.nlm.nih.gov/pubmed/27689018
http://dx.doi.org/10.1016/j.molmet.2016.08.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034684/
https://www.ncbi.nlm.nih.gov/pubmed/27689018
http://dx.doi.org/10.1016/j.molmet.2016.08.014

Ejemplares similares